Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector.
Here are the key catalysts of the unfolding week.
Do Not Allow Advertisers to Use My Personal information
Copyright © 2021,